NCLAT sets aside CAIT plea against CCI nod to Flipkart's acquisition by Walmart

NCLAT sets aside CAIT plea against CCI nod to Flipkart's acquisition by Walmart

A two-member bench of the appellate tribunal headed by Justice S J Mukhopadhaya said CAIT failed to establish its allegations against CCI granting approval for Walmart-Flipkart deal.

PTIUpdated: Thursday, March 12, 2020, 12:47 PM IST
article-image
Flipkart Walmart deal |

New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Thursday dismissed a petition filed by traders' body CAIT against CCI nod to Walmart's USD 16-billion acquisition of Flipkart.

A two-member bench of the appellate tribunal headed by Justice S J Mukhopadhaya said CAIT failed to establish its allegations against CCI granting approval for Walmart-Flipkart deal. NCLAT also said Flipkart was not even made party by CAIT in its plea.

"We find no merit in it, accordingly the appeal is dismissed," said NCLAT, upholding the CCI nod to the deal. The appellate tribunal also observed that the deal would add value to the Flipkart platform.      

The Competition Commission of India (CCI) on August 8, 2018 had said it has approved US retail giant Walmart's acquisition of Flipkart. NCLAT had reserved its order on CAIT's plea in January last year.

RECENT STORIES

Provident Fund Withdrawal Norms Now Simplified, Employees Can Take Out Higher Amount After An Early...

Provident Fund Withdrawal Norms Now Simplified, Employees Can Take Out Higher Amount After An Early...

IRCTC Introduces No-Cancellation Fee Tickets, Making Train Travel More Flexible & Passenger-Friendly

IRCTC Introduces No-Cancellation Fee Tickets, Making Train Travel More Flexible & Passenger-Friendly

What Is Muhurat Trading, Know- How Is It Different From Daily Market Trading?

What Is Muhurat Trading, Know- How Is It Different From Daily Market Trading?

Infrastructure Firm Power Mech Projects Bags Order Worth ₹2,500 Crore From Engineering Firm Bharat...

Infrastructure Firm Power Mech Projects Bags Order Worth ₹2,500 Crore From Engineering Firm Bharat...

Pharmaceutical Company Rubicon Research's Shares List With Premium Of 28% Against ₹485 Issue Price

Pharmaceutical Company Rubicon Research's Shares List With Premium Of 28% Against ₹485 Issue Price